Compare DexCom, Inc. (DXCM) vs Levi Strauss & Co. (LEVI) Price & Performance

DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.

The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.

Levi Strauss (LEVI) trades at $24.85, up 4.46% over 24 hours, with strong fundamentals including a 61.72% gross margin and 9.66% net margin. The stock shows bullish earnings momentum, beating estimates in Q2 2026 with $0.28 EPS versus $0.24 expected, and raised full-year guidance. Technicals are mixed with a bearish overall signal but bullish moving averages, while analyst consensus is strongly positive with 15 buy ratings and a $28.00 price target.

LEVI presents a compelling investment case driven by robust profitability, consistent earnings beats, and dividend growth, though near-term headwinds include tariff pressures and foreign exchange volatility. The stock's current price near support at $24 offers potential upside to the consensus target, but investors should monitor competitive dynamics and macroeconomic risks affecting consumer discretionary spending.